Excitatory amino acid receptor antagonists
OwnerVien Van Khau, Michael Edward Letourneau +1inventors
InventorsVien Van Khau, Michael Edward Letourneau, Michael John Martinelli
Life of this patent
Estimating the term…
Abstract
The present invention provides novel pharmaceutically acceptable salts of the compounds of Formula (I) and Formula (Ia), as well as methods for using the pharmaceutically acceptable salts, and also provides processes for making compounds of Formula (I) and Formula (Ia), or the pharmaceutically acceptable salts thereof. Compounds of formula (I) and formula (Ia) are useful for the treatment of neurological disorders, especially migraine.
Claims27
A pharmaceutically acceptable salt of a compound of the formula:
- 30
- or a prodrug thereof, wherein the pharmaceutically acceptable salt is selected from the group consisting of the d-(−)-mandelic acid salt or the 1,5-naphthalene disulfonic acid salt.
A compound which is 3S,4aR,6S,8aR 6-(((2S)-2-(carboxylic acid)-4,4-difluoropyrrolidinyl)methyl)-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylic acid.D-(−)-mandelic acid.
A compound which is 3S,4aR,6S,8aR 6-(((2S)-2-(carboxylic acid)-4,4-difluoropyrrolidinyl)methyl)-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3carboxylic acid.1,5-naphthalene disulfonic acid.
A pharmaceutically acceptable salt of a compound of the formula:
- 31
- wherein
- R1 and R2 each independently represent hydrogen, (C1-C20)alkyl, (C2-C6)alkenyl, (C1-C6)alkylaryl, (C1-C6)alkyl(C3-C10)cycloalkyl, (C1-C6)alkyl-N,N-C1-C6 dialkylamine, (C1-C6)alkyl-pyrrolidine, (C1-C6)alkyl-piperidine, or (C1-C6)alkyl-morpholine, with the proviso that at least one of R1 and R2 are other than hydrogen;
- wherein the pharmaceutically acceptable salt is selected from the group consisting of the D-(−)-mandelic acid salt or the 1,5-naphthalene disulfonic acid salt.
A compound which is 3S,4aR,6S,8aR Ethyl 6-(((2S)-2-(Ethoxycarbonyl)-4,4-difluoropyrrolidinyl)methyl)-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylate.D-(−)-mandelic acid.
A compound which is 3S,4aR,6S,8aR Ethyl 6-(((2S)-2-(Ethoxycarbonyl)-4,4-difluoropyrrolidinyl)methyl)-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylate.1,5-naphthalene disulfonic acid.
A process for preparing a compound of the formula:
- 32
- wherein
- R1 and R2 each independently represent hydrogen, (C1-C20)alkyl, (C2-C6)alkenyl, (C1-C6)alkylaryl, (C1-C6)alkyl(C3-C10)cycloalkyl, (C1-C6)alkyl-N,N-C1-C6 dialkylamine, (C1-C6)alkyl-pyrrolidine, (C1-C6)alkyl-piperidine, or (C1-C6)alkyl-morpholine, with the proviso that at least one of R1 and R2 are other than hydrogen,
- comprising combining a compound of structure (2)
- 33
- wherein R2 is as defined above, Pg is a suitable nitrogen protecting group, and LgO is a suitable leaving group, with a suitable base in a suitable solvent, followed by addition of a compound of structure (3)
- 34
- wherein R1 is as defined above, followed by oxidation to a compound of structure (5)
- 35
- followed by halogenation and removal of the nitrogen protecting group.
Dependencies are inferred from the claim text.